For research use only. Not for therapeutic Use.
NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors[1].
| Catalog Number | I045249 |
| CAS Number | 22242-89-3 |
| Synonyms | 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-N’-hydroxypyrrolo[2,3-d]pyrimidine-5-carboximidamide |
| Molecular Formula | C12H16N6O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C12H16N6O5/c13-9(17-22)4-1-18(11-6(4)10(14)15-3-16-11)12-8(21)7(20)5(2-19)23-12/h1,3,5,7-8,12,19-22H,2H2,(H2,13,17)(H2,14,15,16)/t5-,7-,8-,12-/m1/s1 |
| InChIKey | UJSNJRHHJZOXPZ-JTFADIMSSA-N |
| SMILES | C1=C(C2=C(N=CN=C2N1C3C(C(C(O3)CO)O)O)N)C(=NO)N |
| Reference | [1]. Dolloff NG, et al. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012;11(11):2321-2330. |
